Xiamen Amoytop Biotech Co Ltd
SSE:688278
Net Margin
Xiamen Amoytop Biotech Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
X
|
Xiamen Amoytop Biotech Co Ltd
SSE:688278
|
30.3B CNY |
30%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
332.9B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
156.1B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
138.8B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.9B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
117.6B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
52.6B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.9B USD |
-11%
|
Xiamen Amoytop Biotech Co Ltd
Glance View
Xiamen Amoytop Biotech Co., Ltd., nestled in the heart of China's coastal city Xiamen, unfolds its narrative as a dynamic player in the biotechnology and healthcare industries. Born from an environment brimming with innovation, the company has diligently carved its niche by focusing on the research, development, and commercialization of diagnostic reagents and test kits. Its core competency lies in crafting solutions designed for precision and reliability, addressing the ever-evolving needs of laboratories and healthcare providers. Through a blend of cutting-edge technology and a keen understanding of biological complexities, Xiamen Amoytop has established itself as a reliable partner, providing essential tools that drive accurate diagnostics and improve patient outcomes across the globe. The company generates revenue by designing and delivering an extensive array of diagnostic products that are indispensable to modern medical practices. From infectious disease diagnostics to blood-based tests, Xiamen Amoytop leverages advancements in molecular biology to offer products that elevate the standards of health diagnostics. By supplying these critical products, the company ensures a steady flow of income sourced from healthcare facilities, research institutions, and diagnostic laboratories both domestically and internationally. Through its robust distribution network and focus on quality assurance, the company continues to expand its market presence, translating its technological prowess into financial growth and global impact.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Xiamen Amoytop Biotech Co Ltd's most recent financial statements, the company has Net Margin of 29.9%.
You don't have any saved screeners yet